QC
UNCY icon

Quadrature Capital’s Unicycive Therapeutics UNCY Stock Holding History

Quadrature Capital’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,917
Closed -$184K – 2069
2026
Q1 		$184K Sell
27,917
-11,197
-29% -$73.4K ﹤0.01% 1139
2025
Q4 		$226K Buy
+39,114
New +$209K ﹤0.01% 940

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Quadrature Capital's UNCY Position: Q2 2026 in Review

Quadrature Capital sold out of Unicycive Therapeutics (UNCY) in Q2 2026, closing a stake of 27,917 shares — an estimated $184K sold.

Quadrature Capital first reported a position in UNCY in Q4 2025 and held it in 2 quarters. The position peaked at $226K in Q4 2025. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Quadrature Capital reported no remaining Unicycive Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 27,917 Unicycive Therapeutics shares in Q2 2026, an estimated $184K.
  • Quadrature Capital first reported a position in Unicycive Therapeutics in Q4 2025 and held it in 2 quarters.
  • Quadrature Capital's Unicycive Therapeutics position peaked at $226K in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.